Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs

EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPR...

Descripción completa

Detalles Bibliográficos
Autores principales: Schernthaner, Guntram, Karasik, Avraham, Abraitienė, Agnė, Ametov, Alexander S., Gaàl, Zsolt, Gumprecht, Janusz, Janež, Andrej, Kaser, Susanne, Lalić, Katarina, Mankovsky, Boris N., Moshkovich, Evgeny, Past, Marju, Prázný, Martin, Radulian, Gabriela, Smirčić Duvnjak, Lea, Tkáč, Ivan, Trušinskis, Kārlis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717330/
https://www.ncbi.nlm.nih.gov/pubmed/31472683
http://dx.doi.org/10.1186/s12933-019-0920-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717330/
https://www.ncbi.nlm.nih.gov/pubmed/31472683
http://dx.doi.org/10.1186/s12933-019-0920-3

Ejemplares similares